Showing results (261-270 of 760) with videos related to

Sort By:
Pageof 76
The New England Journal of Medicine|June 12, 2024
Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell TherapyMetin Ozdemirli, Thomas M Loughney, Emre Deniz, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 8, 2026
The International Myeloma Society Honors the Life and Legacy of Myeloma Pioneer Brian G. M. Durie, MD, PhD (1942-2025)Philippe Moreau, Shaji Kumar, Noopur S Raje, et al.
Oncogene|November 25, 2003
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myelomaTeru Hideshima, Dharminder Chauhan, Toshiaki Hayashi, et al.
Blood|September 18, 2012
Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cellsZe Tian, Jian-jun Zhao, Yu-Tzu Tai, et al.
Blood|August 27, 2020
The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implicationsDaisuke Ogiya, Jiye Liu, Hiroto Ohguchi, et al.
Blood|October 1, 2008
Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3Erik A Nelson, Sarah R Walker, Alicia Kepich, et al.
British Journal of Haematology|September 14, 2012
Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cellsSteffen Klippel, Jana Jakubikova, Jake Delmore, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 1, 2012
Pathological crystallization of human immunoglobulinsYing Wang, Aleksey Lomakin, Teru Hideshima, et al.
British Journal of Haematology|May 11, 2016
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patientsNancy Levin, Andrew Spencer, Simon J Harrison, et al.
Cancer Research|October 20, 2004
Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomibKlaus Podar, Reshma Shringarpure, Yu-Tzu Tai, et al.
Pageof 76